









Markets
/
Stocks
/
nasdaq-veru
/

Veru Inc

VERU

3.470USD

-0.100-2.80%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

5.08MMarket Cap

LossP/E TTM



Veru Inc

3.470

-0.100-2.80%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

182 / 506

Overall Ranking

297 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

21.250

Target Price

+495.24%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.

Growing

The company is in a growing phase, with the latest annual income totaling USD 16.89M.

Overvalued

The company’s latest PE is -0.20, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 66.80M shares, decreasing 33.37% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 640.69K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.67.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 4.98, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

4.98

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.10

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

0.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.82

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

5.00

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.21, which is 279.33% below the recent high of -0.79 and -1212.30% above the recent low of -2.74.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 182/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Veru Inc is 22.50, with a high of 30.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

21.250

Target Price

+495.24%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Veru Inc

VERU

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.75, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.94 and the support level at 3.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.75

Change

-0.22

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.177

Neutral

RSI(14)

58.374

Neutral

STOCH(KDJ)(9,3,3)

31.866

Sell

ATR(14)

0.223

High Vlolatility

CCI(14)

27.224

Neutral

Williams %R

65.474

Sell

TRIX(12,20)

1.580

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

3.536

Sell

MA10

3.539

Sell

MA20

3.456

Buy

MA50

2.229

Buy

MA100

1.399

Buy

MA200

1.010

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 45.57%, representing a quarter-over-quarter decrease of 4.39%. The largest institutional shareholder is The Vanguard, holding a total of 640.69K shares, representing 4.37% of shares outstanding, with 2.87% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fisch (Harry)

8.01M

Steiner (Mitchell Shuster)

7.09M

The Vanguard Group, Inc.

Star Investors

6.25M

+0.50%

Frost Gamma Investments Trust

5.10M

MPM BioImpact LLC

6.59M

+53.84%

PVG Asset Management Corporation

1.60M

+52.48%

Geode Capital Management, L.L.C.

3.03M

+1.18%

BlackRock Institutional Trust Company, N.A.

7.95M

+4.31%

UBS Financial Services, Inc.

1.80M

+443.98%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.08, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.77. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.